MktsMarkets

TransCode Therapeutics, Inc.
NASDAQ: RNAZKey statistics
RNAZ News
Stories mentioning RNAZ from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 5,107 | 5,475 | 3,161 | 2,566 | 2,220 | 3,638 | 1,227 | 3,082 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 17,755 | 16,027 | 4,561 | 4,221 | 3,171 | 5,093 | 2,165 | 5,114 |
| Operating Income (Loss) | (17,755) | (16,027) | (4,561) | (4,221) | (3,171) | (5,093) | (2,165) | (5,114) |
| Interest Income | 92.00 | 79.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.00 | 11.00 | 4.00 | ||||
| Other Expense | ||||||||
| Pretax Income | (17,554) | (12,085) | ||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Net Income (Loss) | (17,785) | (13,443) | (4,856) | (4,277) | (12,085) | (5,916) | (2,321) | (5,191) |
| Earnings Per Share (Basic) | (21.28) | (19.48) | (5.82) | (5.13) | (70.16) | (455.08) | (146.06) | (680.23) |
| Earnings Per Share (Diluted) | (21.28) | (19.48) | (5.82) | (5.13) | (70.16) | (455.08) | (146.06) | (680.23) |
| Weighted Average Shares Outstanding (Basic) | 917.00 | 690.00 | 834.00 | 834.00 | 172.00 | 13.00 | 16.00 | 8.00 |
| Weighted Average Shares Outstanding (Diluted) | 917.00 | 690.00 | 834.00 | 834.00 | 172.00 | 13.00 | 16.00 | 8.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RNAZ
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a stock listed on the Nasdaq Stock Market under the ticker symbol RNAZ. It last traded at $1.51 (Nov 6, 2026, 3:58 PM ET), unchanged on the day. That gives TransCode Therapeutics a market capitalisation of $25.2M.
Over the past 52 weeks RNAZ has traded between $1.45 and $12.60.
For the quarter ended Mar 31, 2026 it reported a net loss of $17.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$17.8M |
| Dec 31, 2025 | — | -$13.4M |
| Sep 30, 2025 | — | -$4.9M |
| Jun 30, 2025 | — | -$4.3M |
From TransCode Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…